| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Evidence-Based Laboratory Medicine and Test Utilization |
Departments of1 Laboratory Medicine & Immunology and 2 Rheumatology, University Hospital Leuven, Belgium.
aAddress correspondence to this author at: Department of Laboratory Medicine, Immunology, University Hospital Leuven, Herestraat 49, B-3000 Leuven, Belgium. Fax 0032-16-347931; e-mail xavier.bossuyt{at}uz.kuleuven.ac.be
Background: Several anticitrullinated protein/peptide antibodies (ACPA) assays have been reported to be of diagnostic value for rheumatoid arthritis (RA). We evaluated the technical performance and diagnostic accuracy of 6 ELISAs for the detection of antibodies to citrullinated protein/peptide antigens.
Methods: ACPA were determined in 298 serum samples using 6 commercially available ACPA assays. One hundred two samples were from RA patients, including patients with early and established RA, and 196 were from controls, including patients with psoriatic arthritis, connective tissue diseases, organ-specific autoimmune diseases, and a group of consecutive patients for whom a rheumatologist ordered anticyclic citrullinated peptide (CCP) antibodies. The ELISA reagent sets under study were Citrullinated Protein Antibodies (Genesis), Anti-MCV (Orgentec), Immunoscan RA (Euro-Diagnostica), Anti-CCP IgG ELISA (Euroimmun), EliATM CCP (Phadia), and Quanta LiteTM CCP3 IgG ELISA (Inova). Technical performance (imprecision, linearity, correlation, and agreement) and diagnostic accuracy (sensitivity and specificity) were compared.
Results: Variable technical performance was noted among the different ACPA assays, with some assays displaying poor reproducibility and bad linearity. ACPA results were well correlated among assays with the same antigen specificity, but the numerical values reported for each assay differed widely. Using cutoff values proposed by the manufacturer, diagnostic sensitivities ranged between 69.6% and 77.5% and specificities between 87.8% and 96.4%. The areas under the ROC curves were comparable among the different assays.
Conclusions: Overall diagnostic performance of ACPA assays is comparable among the different assays, but standardization is needed. For some assays, analytical characteristics could be improved.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  A. Murray, C. J. Chapman, G. Healey, L. J. Peek, G. Parsons, D. Baldwin, A. Barnes, H. F. Sewell, H. A. Fritsche, and J. F. R. Robertson Technical validation of an autoantibody test for lung cancer Ann. Onc., February 2, 2010; (2010): mdp606v1 - mdp606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J Luime, E M Colin, J M W Hazes, and E Lubberts Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review Ann Rheum Dis, February 1, 2010; 69(2): 337 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S W Syversen, G L Goll, D van der Heijde, R Landewe, B A Lie, S Odegard, T Uhlig, P I Gaarder, and T K Kvien Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study Ann Rheum Dis, February 1, 2010; 69(2): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. KAKUMANU, E. S. SOBEL, S. NARAIN, Y. LI, J. AKAOGI, Y. YAMASAKI, M. S. SEGAL, P. C. HAHN, E. K.L. CHAN, W. H. REEVES, et al. Citrulline Dependence of Anti-Cyclic Citrullinated Peptide Antibodies in Systemic Lupus Erythematosus as a Marker of Deforming/Erosive Arthritis J Rheumatol, December 1, 2009; 36(12): 2682 - 2690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Snir, M Widhe, C von Spee, J Lindberg, L Padyukov, K Lundberg, A Engstrom, P J Venables, J Lundeberg, R Holmdahl, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles Ann Rheum Dis, May 1, 2009; 68(5): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X Bossuyt, D Coenen, S Fieuws, P Verschueren, R Westhovens, and N Blanckaert Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor Ann Rheum Dis, February 1, 2009; 68(2): 287 - 289. [Full Text] [PDF]
|
|
|
|
|
|
X. Bossuyt, C. Louche, and A. Wiik Standardisation in clinical laboratory medicine: an ethical reflection Ann Rheum Dis, August 1, 2008; 67(8): 1061 - 1063. [Full Text] [PDF]
|
|
|
|
|
|
K Kitahara, K Takagi, Y Kusunoki, S Nishio, T Nozaki, H Inomata, M Takei, S Sawada, and S Kawai Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis Ann Rheum Dis, July 1, 2008; 67(7): 1059 - 1060. [Full Text] [PDF]
|
|
|
|
|
|
B Vander Cruyssen, L Nogueira, J Van Praet, D Deforce, D Elewaut, G Serre, and F De Keyser Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis Ann Rheum Dis, April 1, 2008; 67(4): 542 - 546. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
